A promising alternative anti-HBV agent: The targeted ribonuclease

International Journal of Molecular Medicine

Volumn 26, Issue 1, 2010, Pages 51-56

  Li, Yinghui ^a   Zhao, Ya ^a   Liu, Jun ^a   Huang, Yuxiao ^a   Liu, Zhongxiang ^a   Xue, Caifang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Targeted ribonuclease; Therapy

Indexed keywords

ANTIVIRUS AGENT; BETA GALACTOSIDASE; CAPSID PROTEIN; EOSINOPHIL PROTEIN X; HBV TARGETED RIBONUCLEASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYBRID PROTEIN; RIBONUCLEASE; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; RNA DEGRADATION; SEROLOGY; SUPERNATANT; VIRUS INACTIVATION; VIRUS MORPHOGENESIS; VIRUS REPLICATION; WILD TYPE;

ELECTROPHORESIS, POLYACRYLAMIDE GEL; EOSINOPHIL-DERIVED NEUROTOXIN; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; MUTATION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; RNA, NEOPLASM; RNA, VIRAL; TRANSFECTION; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 77954742788     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000434     Document Type: Article

References (36)

1. Ganem D and Varmus HE: The molecular biology of the hepatitis B viruses. Annu Rev Biochem 56: 651-693, 1987.
2. Lau JY and Wright TL: Molecular virology and pathogenesis of hepatitis B. Lancet 342: 1335-1340, 1993.
3. Tang ZY: Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 7: 445-454, 2001. (Pubitemid 32780652)
4. Hoofnagle JH: Therapy of viral hepatitis. Digestion 59: 563-578, 1998.
5. Hilleman MR: Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19: 1837-1848, 2001.
6. Francois G, Kew M, Van Damme P, Mphahlele MJ and Meheus A: Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 19: 3799-3815, 2001.
7. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS and Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119: 312-323, 1993. (Pubitemid 23319890)
8. Hoofnagle JH and di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 336: 347-356, 1997.
9. Nevens F, Main J, Honkoop P, et al: Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113: 1258-1263, 1997.
10. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM and Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24: 714-717, 1996.
11. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A and Pastore G: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32: 300-306, 2000.
12. Tung FY and Bowen SW: Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci 3: a11-a15, 1998.
13. Zhoug S, Wen SM, Zhang DF, Wang QL, Wang SQ and Ren H: Sequencing of PCR amplified HBV DNA pre-c and c regions in the 2.2.15 cells and antiviral action by targeted antisense oligonucleotide directed against sequence. World J Gastroenterol 4: 434-436, 1998.
14. Liu J, Li YH, Xue CF, Ding J, Gong WD, Zhao Y and Huang YX: Targeted ribonuclease can inhibit replication of hepatitis B virus. World J Gastroenterol 9: 295-299, 2003. (Pubitemid 36215808)
15. Buchner J, Pastan I and Brinkmann U: A method for increasing the yield of properly folded recombinant fusion proteins: singlechain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205: 263-270, 1992.
16. Newton DL, Nicholls PJ, Rybak SM and Youle RJ: Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J Biol Chem 269: 26739-26745, 1994.
17. Laras A, Koskinas J and Hadziyannis SJ: In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 295: 86-96, 2002.
18. Wands JR, Geissler M, Putlitz JZ, et al: Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J Gastroenterol Hepatol 12: S354-S369, 1997.
19. Beck J and Nassal M: Hepatitis B virus replication. World J Gastroenterol 13: 48-64, 2007.
20. Scaglioni PP, Melegari M and Wands JR: Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 205: 112-120, 1994. (Pubitemid 24360596)
21. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR and Wands J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 24: 1010-1017, 1996.
22. Von Weizsacker F, Wieland S and Blum HE: Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. Hepatology 24: 294-299, 1996.
23. Von Weizsacker F, Kock J, Wieland S, Offensperger WB and Blum HE: Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 30: 308-315, 1999.
24. Natsoulis G and Boeke JD: New antiviral strategy using capsid-nuclease fusion proteins. Nature 352: 632-635, 1991. (Pubitemid 21912396)
25. Boeke JD and Hahn B: Destroying retroviruses from within. Trends Microbiol 4: 421-426, 1996.
26. Giordano V, Jin DY, Rekosh D and Jeang KT: Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol. Virology 267: 174-184, 2000.
27. Sullenger BA and Cech TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262: 1566-1569, 1993.
28. Tepper RI, Pattengale PK and Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512, 1989.
29. Tepper RI, Coffman RL and Leder P: An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551, 1992.
30. Liu J, Li YH, Ding J, Gong WD, Xue CF, Zhao Y and Huang YX: Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR. World J Gastroenterol 10: 2883-2885, 2004.
31. Saxena SK, Gravell M, Wu YN, Mikulski SM, Shogen K, Ardelt W and Youle RJ: Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem 271: 20783-20788, 1996.
32. Tuttleman JS, Pourcel C and Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47: 451-460, 1986. (Pubitemid 17210159)
33. Seeger C and Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev 64: 51-68, 2000.
34. Zhao Y, Li Y, Liu J, et al: Adenoviral-vector mediated transfer of HBV-targeted ribonuclease can inhibit HBV replication in vivo. Biochem Biophys Res Commun 371: 541-545, 2008.
35. Rosenberg HF and Dyer KD: Eosinophil cationic protein and eosinophil-derived neurotoxin. Evolution of novel function in a primate ribonuclease gene family. J Biol Chem 270: 21539-21544, 1995.
36. Brinkmann U, Buchner J and Pastan I: Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. Proc Natl Acad Sci USA 89: 3075-3079, 1992.